Literature DB >> 2757894

Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man.

S A Ward1, W M Watkins, E Mberu, J E Saunders, D K Koech, H M Gilles, R E Howells, A M Breckenridge.   

Abstract

1. The metabolism of proguanil to the active metabolite cycloguanil has been evaluated in 135 British Troops and 26 Kenyan schoolchildren. 2. Large inter-subject variability was observed in both plasma and urinary concentrations of proguanil and cycloguanil after standard doses of drug. 3. Based on the ratio of proguanil to cycloguanil (P/C) in urine the British troops formed a non-normal distribution. 90% of the population formed a discrete distribution with P/C ranging from 0.5 to 9.0 while the remaining 10% were scattered throughout the distribution to an extreme value of 39. A similar pattern of variability was observed using P/C from a 6 h plasma sample. 4. This variability was due to differences in the ability of individuals to metabolise proguanil to cycloguanil. 5. Thirteen schoolchildren who had experienced malaria during prophylaxis with proguanil and thirteen matched controls each received proguanil (100 mg). We could not discriminate between the two groups based on P/C ratio in either a 6 h plasma or 0-6 h urine sample.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2757894      PMCID: PMC1379805          DOI: 10.1111/j.1365-2125.1989.tb03440.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  A metabolite of paludrine with high antimalarial activity.

Authors:  H C CARRINGTON; A F CROWTHER; D G DAVEY; A A LEVI; F L ROSE
Journal:  Nature       Date:  1951-12-22       Impact factor: 49.962

3.  Simultaneous measurement of proguanil and cycloguanil in human plasma by high-performance liquid chromatography.

Authors:  M D Edstein
Journal:  J Chromatogr       Date:  1986-07-11

4.  High-performance liquid chromatographic method for the determination of proguanil and cycloguanil in biological fluids.

Authors:  J A Kelly; K A Fletcher
Journal:  J Chromatogr       Date:  1986-09-05

5.  Determination of proguanil and its metabolites cycloguanil and 4-chlorophenylbiguanide in plasma, whole blood and urine by high-performance liquid chromatography.

Authors:  R B Taylor; R R Moody; N A Ochekpe
Journal:  J Chromatogr       Date:  1987-05-15

6.  Strategies for the prevention of malaria in travellers: comparison of drug regimens by means of risk-benefit analysis.

Authors:  T E Peto; C F Gilks
Journal:  Lancet       Date:  1986-05-31       Impact factor: 79.321

7.  Plasma Paludrine levels--some observations in Commonwealth troops in the Far East 1970.

Authors:  D E Worsley
Journal:  J R Army Med Corps       Date:  1985-10       Impact factor: 1.285

8.  High-performance liquid chromatography of proguanil, cycloguanil and 4-chlorophenylbiguanide using hydrophobic pairing ion and its application to serum assay.

Authors:  R R Moody; A B Selkirk; R B Taylor
Journal:  J Chromatogr       Date:  1980-06-13

9.  A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil.

Authors:  W M Watkins; J D Chulay; D G Sixsmith; H C Spencer; R E Howells
Journal:  J Pharm Pharmacol       Date:  1987-04       Impact factor: 3.765

10.  Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects.

Authors:  Y Wattanagoon; R B Taylor; R R Moody; N A Ochekpe; S Looareesuwan; N J White
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

  10 in total
  21 in total

Review 1.  The evolution of drug-resistant malaria: the role of drug elimination half-life.

Authors:  Ian M Hastings; William M Watkins; Nicholas J White
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2002-04-29       Impact factor: 6.237

2.  The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism.

Authors:  N A Helsby; S A Ward; G Edwards; R E Howells; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

Review 3.  Risks and benefits of prophylactic antimalarial drugs.

Authors:  A Breckenridge
Journal:  BMJ       Date:  1989-10-28

4.  The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women.

Authors:  K Na-Bangchang; C Manyando; R Ruengweerayut; D Kioy; M Mulenga; G B Miller; J Konsil
Journal:  Eur J Clin Pharmacol       Date:  2005-07-23       Impact factor: 2.953

5.  Evidence for the polymorphic oxidation of debrisoquine and proguanil in a Khmer (Cambodian) population.

Authors:  S Wanwimolruk; M R Thou; D J Woods
Journal:  Br J Clin Pharmacol       Date:  1995-08       Impact factor: 4.335

Review 6.  Genetically determined adverse drug reactions involving metabolism.

Authors:  M S Lennard
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

7.  Oxidative activation of proguanil and dapsone acetylation in Thai soldiers.

Authors:  M D Edstein; G D Shanks; P Teja-Isavadharm; K H Rieckmann; H K Webster
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

8.  The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides.

Authors:  J D Wright; N A Helsby; S A Ward
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

9.  Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark.

Authors:  K Brøsen; E Skjelbo; H Flachs
Journal:  Br J Clin Pharmacol       Date:  1993-08       Impact factor: 4.335

10.  In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase.

Authors:  D J Birkett; D Rees; T Andersson; F J Gonzalez; J O Miners; M E Veronese
Journal:  Br J Clin Pharmacol       Date:  1994-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.